Axsome Therapeutics (AXSM) Misses Q2 EPS by 36c, offers guidance

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.67), $0.36 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $87.2 million versus the consensus estimate of $86.66 million.

Financial Guidance

Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Pfizer executive says China now leads Europe in drug innovation